Malaysia
Search
Sign In
Change Password
Points
Sign Out
Top Medical News
Increased long-term blood pressure (BP) variability is a predictor of chronic kidney disease (CKD) in patients with type 2 diabetes and hypertension, suggests a recent study.
Total thyroidectomy, but not medical therapy, improves health-related quality of life and fatigue in patients with Hashimoto disease, a chronic autoimmune thyroiditis, a Norway study has shown.
An association exists between drinking coffee and favourable profiles of several biomarkers in key metabolic and inflammatory pathways, a US study has shown.
Drinking sugar sweetened beverages in large amounts may lead to a significant weight gain over a 4–5-year period in low-resource settings, a study has found.
Endogenous testosterone appears to play a significant role in thromboembolism, heart failure (HF) and myocardial infarction (MI), with rates of these conditions higher in men than women, according to a recent study. Existing treatment can control endogenous testosterone, which can be a modifiable risk factor for HF and thromboembolism.
Specific metabolic parameters such as waist circumference and C-reactive protein are elevated, whereas high-density lipoprotein (HDL) cholesterol levels are reduced in the presence of high levels of depression and perceived stress, a study has reported.
The newly developed VikingSlice software for computed tomography (CT) body composition analysis is fast and has good reliability that is comparable to commercial software SliceOMatic for estimating adipose tissue and skeletal muscle cross-sectional areas (CSAs), according to a recent study.
Special Reports
At the Abbott-sponsored symposium held during the 9th Malaysian Endocrine and Metabolic Society Annual Congres sat Hilton Kuala Lumpur, Dr Zanariah Hussein shared her insights into the important role of an emerging marker of hypercholesterolaemia, and its relationship with cardiovascular (CV) and diabetic retinopathy (DR) risks.
At the AstraZeneca-sponsored symposium held during the 9th Malaysian Endocrine and Metabolic Society Annual Congress at Hilton Kuala Lumpur, Professor Ronald Ma highlighted the role of a novel combination therapy in reducing HbA1c levels while simultaneously providing cardiovascular (CV) protection to improve patient outcomes.
The FOURIER trial previously demonstrated that adding the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab to background statin therapy lowered LDL-cholesterol (LDL-C) below target levels and significantly reduced the risks of cardiovascular (CV) events in patients with atherosclerotic cardiovascular disease (ASCVD). At the European Society of Cardiology (ESC) Congress 2018 in Munich, Germany, experts reiterated how evolocumab helps lower LDL-C levels and reduces CV events even in patients with various comorbidities.
At the recent ‘Reinforced for the Glycaemic Challenge’ symposium held at Shangri-la Hotel, Kuala Lumpur, Associate Professor Dr Alexander Tan, Professor Dr Chee Kok Han and Dr Chan Siew Pheng shared their insights into the importance of achieving glycaemic control in patients with type 2 diabetes mellitus (T2DM), while simultaneously providing them with cardiovascular protection.
At a recent lunch symposium held in conjunction with the 1st Malaysian Advances in Women’s Health Congress 2016, Professor Dr Jamiyah Hassan imparted clinical updates and strategies for the optimization of hormone replacement therapy in menopausal women. Highlights from her presentation are summarized below.
At the Diabetes Asia 2016 Conference organized by the National Diabetes Institute, Professor Jean Claude Mbanya presented the case for why gliclazide modified release (MR; Diamicron® MR, Servier) should be the treatment of choice for early and aggressive control of type 2 diabetes (T2D).
BASALOG – Insulin glargine (rDNA) 100 IU/mL soln for inj (cartridge) – CCM Pharmaceuticals
Conference Reports
Switching from animal to plant-based proteins in one’s daily diet is linked to many benefits, one of which is the management of type 2 diabetes mellitus, says a researcher.
Type 2 diabetes is closely linked to obesity, which in turn, increases the risk for cardiovascular diseases (which includes mainly heart disease and stroke), muscle and bone diseases; and cancers. Obesity-related cancers include breast, endometrial, ovarian, colorectal, pancreatic, renal, liver and gallbladder cancer. [Lancet 2008;371(9612):569–578]
In what many clinicians believed was a rare breakthrough, the prescription fish oil icosapent ethyl cut the risk of ischaemic events among statin-treated patients with high triglyceride levels and either cardiovascular disease (CVD) or diabetes in the REDUCE-IT* trial, putting fish oil on the front burner.
The Ministry of Health (MOH), Malaysia continues to strive towards achieving the optimal glycaemic target and reducing the impact of diabetes complications among patients.
Higher ideal levels of dietary intake, physical activity, smoking, blood pressure (BP), cholesterol and body mass index (BMI) are associated with a dose-dependent lower risk of type 2 diabetes (T2D) for individuals with normal fasting glucose but not impaired fasting glucose, according to a study presented at the American Heart Association (AHA) Scientific Sessions 2018.
Slideshow: Highlights from the American Heart Association (AHA) Scientific Sessions 2018
Treatment with the SGLT2i* empagliflozin appears to significantly reduce left ventricular mass (LVM) among patients with type 2 diabetes (T2D), according to results of the EMPA-HEART** CardioLink-6 trial presented at AHA 2018.
Multimedia
